Orphazyme A/S (OZYMF)
USD 90.0
(0.0%)
USD 90.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.04 Thousand DKK | 34.43% |
| 2022 | -41.24 Million USD | -223.26% |
| 2021 | -12.75 Million DKK | 87.25% |
| 2020 | -100.03 Million DKK | -98.21% |
| 2019 | -50.46 Million DKK | 78.21% |
| 2018 | -231.65 Million DKK | -76.78% |
| 2017 | -131.04 Million DKK | -106.74% |
| 2016 | -63.38 Million DKK | -19.4% |
| 2015 | -53.08 Million DKK | -43.09% |
| 2014 | -37.09 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -213.8 Thousand USD | 0.0% |
| 2023 FY | -27.04 Million DKK | 34.43% |
| 2023 Q2 | -1.87 Million USD | 0.0% |
| 2023 Q4 | -2.1 Million USD | 0.0% |
| 2022 FY | -41.24 Million USD | -223.26% |
| 2022 Q4 | -2 Million USD | 0.0% |
| 2022 Q2 | -3.83 Million USD | 0.0% |
| 2021 FY | -12.75 Million DKK | 87.25% |
| 2020 FY | -100.03 Million DKK | -98.21% |
| 2019 FY | -50.46 Million DKK | 78.21% |
| 2018 FY | -231.65 Million DKK | -76.78% |
| 2017 FY | -131.04 Million DKK | -106.74% |
| 2016 FY | -63.38 Million DKK | -19.4% |
| 2015 FY | -53.08 Million DKK | -43.09% |
| 2014 FY | -37.09 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.848% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 99.464% |
| CSL Limited | 3.7 Billion USD | 100.001% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.033% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 96.064% |
| BioStem Technologies, Inc. | -7.77 Million USD | 99.652% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 97.847% |
| Qrons Inc. | -643.67 Thousand USD | 95.799% |
| Nascent Biotech, Inc. | -2.22 Million USD | 98.787% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.951% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 99.593% |
| Skye Bioscience, Inc. | -13.67 Million USD | 99.802% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 93.492% |
| Rebus Holdings, Inc. | -664 Thousand USD | 95.928% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.83% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 97.975% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.993% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 93.059% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.962% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.55% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 89.668% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.964% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 99.051% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 98.24% |
| Mesoblast Limited | -84.14 Million USD | 99.968% |
| Marizyme, Inc. | -34.08 Million USD | 99.921% |
| Genus plc | 6.4 Million USD | 100.423% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.278% |
| Pharming Group N.V. | -4.87 Million USD | 99.446% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 98.639% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 97.097% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 99.676% |
| ContraFect Corporation | -56.88 Million USD | 99.952% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 99.406% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 98.071% |
| IMV Inc. | -38.67 Million USD | 99.93% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 99.017% |
| MultiCell Technologies, Inc. | -722.81 USD | -3641.094% |
| ONE Bio Corp. | 13.68 Million USD | 100.198% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.278% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.954% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 94.402% |
| Q BioMed Inc. | -3.44 Million USD | 99.215% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.764% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 98.971% |
| Biomind Labs Inc. | -1 Million USD | 97.322% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.951% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 99.068% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 98.55% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 9.719% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 98.601% |
| GB Sciences, Inc. | -1.42 Million USD | 98.096% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.721% |
| HST Global, Inc. | -140.9 Thousand USD | 80.809% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 97.596% |
| Halberd Corporation | -75.05 Thousand USD | 63.969% |
| Enzolytics Inc. | -2.14 Million USD | 98.742% |
| Agentix Corp. | -1.37 Million USD | 98.029% |
| Resverlogix Corp. | -12.74 Million USD | 99.788% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 99.147% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 97.41% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 99.074% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 98.288% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 99.206% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.404% |
| Zenith Capital Corp. | -8.94 Million USD | 99.698% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -55.221% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 98.899% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 84.234% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 98.651% |
| Kadimastem Ltd | -3.04 Million USD | 99.111% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 97.252% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 85.1% |
| LadRx Corporation | -3.82 Million USD | 99.293% |
| Cell Source, Inc. | -4.32 Million USD | 99.375% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 96.064% |
| NovAccess Global Inc. | -2.46 Million USD | 98.904% |
| Affymax, Inc. | -15.04 Million USD | 99.82% |
| Itoco Inc. | -919.14 Thousand USD | 97.058% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 99.362% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 97.583% |
| Mobile Lads Corp. | -554.55 Thousand USD | 95.124% |
| CytoDyn Inc. | -18.05 Million USD | 99.85% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -7.433% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 87.713% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 95.212% |
| SYBLEU INC | -149.18 Thousand USD | 81.874% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 98.511% |
| International Stem Cell Corporation | -663 Thousand USD | 95.921% |
| Bioxytran, Inc. | -3.82 Million USD | 99.292% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 48.63% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -32.945% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.925% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 98.329% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 96.325% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 99.131% |
| Neutra Corp. | -229.48 Thousand USD | 88.217% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.846% |
| PureTech Health plc | -146.19 Million USD | 99.982% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.874% |
| IXICO plc | -1.43 Million USD | 98.118% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 99.715% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.978% |
| CSL Limited | 3.81 Billion USD | 100.001% |
| Cellectis S.A. | -108.85 Million USD | 99.975% |